Inclusion Criteria:
- Patient is being treated for Rheumatoid Arthritis (RA) at a Rheumatology Clinic at the University of Michigan or another by rheumatologist and reports being prescribed at least one of the following medications:
- Methotrexate (Trexall, Rheumatrex)
- Hydroxychloroquine (Plaquenil)
- Sulfasalazine (Azulfadine)
- Leflunomide (Arava)
- Tocilizumab (Actemra)
- Tumor necrosis factor inhibitor (TNFi), including:
Adalimumab (Humira) Etanercept (Enbrel) Certolizumab pegol (Cimzia) Golimumab (Simponi) Infliximab (Remicade)
- Abatacept (Orencia)
- Tocilizumab (Actemra)
- Janus kinase inhibitor (JAKi), including:
Tofacitinib (Xeljanz) Baracitinib (Olumiant) Upadacitinib (Rinvoq)
o Rituximab (Rituxan)
Exclusion Criteria:
- Visual or hearing difficulties that would preclude participation,
- Do not speak or read English
- Do not have access to smart phone with access to mobile applications
- Severe psychiatric disorders including history of substance abuse disorders,
- Individuals on high doses of opioids (over 100 oral morphine equivalents)
- Taking blood thinners, including warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)
- Thrombocytopenia (low platelet count)
- Expecting to receive surgery within the next year for their RA
- Pregnancy or breast feeding, or anticipate pregnancy in next year,
- Actively applying for disability or compensation, or actively involved in litigation.
- Anything at the discretion of the principal investigator or study team